Fig. 8From: Inhibition of GSK3β activity alleviates acute liver failure via suppressing multiple programmed cell deathThe schematic shows that the GSK3β inhibitor TDZD-8 ameliorates cell death via the TAK1 pathway. the combination of LPS/D-Gal activates GSK3β and reduces TRAF6 levels, thereby increasing HDAC3 levels and reducing TAK1, promoting hepatocyte apoptosis, pyroptosis and necroptosisBack to article page